NCT02928978 - Ruxolitinib for Premalignant Breast Disease | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

May 13, 2018

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions

Ductal Carcinoma In SituAtypical Lobular HyperplasiaAtypical Ductal HyperplasiaLobular Carcinoma In Situ

Interventions

DRUG

Ruxolitinib

tablet (taken by mouth)

DRUG

Placebo (for Ruxolitinib)

tablet (taken by mouth)

Trial Locations (8)

Montefiore Medical Center, The Bronx

University of North Carolina at Chapel Hill, Chapel Hill

University of Alabama at Birmingham, Birmingham

Vanderbilt-Ingram Cancer Center, Nashville

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

University of Texas MD Anderson Cancer Center, Houston

Harris Health System - Smith Clinic, Houston

O'Quinn Medical Tower - McNair Campus; Dan L Duncan Comprehensive Cancer Center, Houston